Antihypertensive Efficacy of Combination Treatment with Olmesartan Medoxomil and Amlodipine

Because it increases the risk of cardiovascular disease, hypertension is one of most important causes of mortality. To achieve a target blood pressure of 140/90 mmHg, many patients with hypertension require combination therapy. One useful option is a fixed-dose combination of olmesartan and amlodipine. For example, the COACH trial showed that using these drugs in long-term combination therapy, rather than in monotherapy, had many advantages including a lower incidence of adverse events and stronger antihyperten- sive potency. Numerous other clinical trials have supported these findings for olmesartan and amlodipine combination therapy. Given these results, we conclude that combination therapy with olmesartan and amlodipine is clinically useful for the treatment of blood pressure control and may improve target organ protection.